Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors

Introduction: The optimal treatment of estrogen receptor-positive (ER +) metastatic breast cancer (MBC) after progression on cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) is unknown. Methods: We conducted a systematic review and network meta-analysis (NMA) of phase-II/-III randomized trials of ER...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2025-01-01
Saila:	Current Oncology
Gaiak:	metastatic breast cancer CDK4/6 inhibitor hormone receptor-positive cancer SERD HER2-low breast cancer AKT inhibitor
Sarrera elektronikoa:	https://www.mdpi.com/1718-7729/32/1/53
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!